Who Owns Annexon Company?

Annexon Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Annexon Company?

Navigating the complex world of biotech requires understanding who steers the ship. Annexon Company, a key player in neurodegenerative disease research, offers a fascinating case study in corporate ownership. Unraveling Annexon SWOT Analysis reveals how ownership structure impacts strategy and success. This analysis delves into the evolution of Annexon's ownership, from its founding to its current status as a public entity.

Understanding Annexon ownership is critical for investors and stakeholders alike. The shift from private to public ownership, coupled with the influence of institutional investors, shapes the company's future. This exploration of Annexon Biosciences will examine key players, including the founders, institutional investors, and the impact of their holdings on the company's direction. Analyzing Annexon's stock ownership details provides valuable insights.

Annexon, Inc. was established in 2011. The company was co-founded by Dr. Arnon Rosenthal and Dr. Ben Barres. Their combined expertise in neurobiology and the complement system formed the scientific foundation of the company.

Dr. Ben Barres, a former member of the National Academy of Sciences and a Stanford University professor, was a key figure in understanding complement-mediated neurodegeneration. His research revealed that C1q drives synapse loss in neurodegenerative disorders. Dr. Arnon Rosenthal also contributed significantly to the development of ANX005, a key drug candidate for Annexon.

While the exact initial equity distribution between the founders isn't publicly available, their scientific contributions and leadership were fundamental to Annexon's early direction. Their vision focused on the classical complement pathway, specifically targeting C1q to halt inflammatory cascades and restore biological function. This focus has driven the company's research and development efforts from its inception.

Early Funding and Investors

Annexon secured early funding from several prominent firms. These included New Enterprise Associates, Blackstone, and Bain Capital. These investments were crucial for the initial research and development phases of the company. These early backers played a crucial role in providing the capital necessary for initial research and development.

• Annexon raised a total of $256 million through six funding rounds.
• The company's focus on the complement pathway was a direct result of the founders' scientific vision.
• The company's headquarters is located in Brisbane, California.
• Annexon is a publicly traded company; you can find information about the marketing strategy of Annexon.

Annexon SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The evolution of ownership for Annexon, Inc. has been significantly shaped by its transition to a publicly traded entity. The initial public offering (IPO) in 2020, which listed the company on the Nasdaq Global Select Market under the ticker 'ANNX', was a pivotal moment. This event not only provided capital for the company's pipeline development and organizational growth but also initiated a shift in its ownership structure, opening it up to a broader range of investors, particularly institutional ones. The IPO marked a move from private to public ownership, fundamentally changing the dynamics of the company's stakeholders and their influence.

As of June 11, 2025, Annexon's market capitalization is valued at approximately $276 million, with roughly 110 million shares outstanding. This valuation reflects the market's assessment of the company's current and future prospects, influenced by factors such as clinical trial outcomes, pipeline progress, and overall market conditions within the biotechnology sector. The IPO and subsequent market performance have been key factors in shaping the company's investor base and its strategic direction.

The ownership structure of Annexon is predominantly held by institutional investors. As of May 2025, institutional investors control around 99.87% of the shares. This high percentage is typical for biotech companies, where specialized funds and large asset managers often take substantial positions. According to filings from March 31, 2025, Annexon had 337 institutional owners, collectively holding 123,243,946 shares. Major shareholders as of March 31, 2025, included Fmr Llc, holding 13,262,328 shares, BlackRock, Inc. with 8,526,506 shares, and Vanguard Group Inc. with 5,379,659 shares. Other significant institutional holders include Satter Management Co., L.p., Bvf Inc/il, Redmile Group, LLC, Bain Capital Life Sciences Investors, LLC, Bellevue Group AG, Logos Global Management LP, and Ameriprise Financial Inc. Mutual funds have also increased their holdings, from 51.65% in April 2025 to 52.88% in May 2025. Insider ownership, as of May 2025, is approximately 0.58%. The shift towards institutional ownership reflects a common trajectory for public biopharmaceutical companies, where specialized funds and large asset managers acquire significant stakes, influencing company strategy through their investment decisions and engagement with management. For more details on the company's financial model, consider reading about the Revenue Streams & Business Model of Annexon.

Annexon Ownership Insights

Annexon's ownership structure is primarily dominated by institutional investors, reflecting a trend common in the biotech sector.

• Institutional investors hold approximately 99.87% of the shares as of May 2025.
• Major shareholders include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc.
• The IPO in 2020 was a key event in shaping the company's ownership landscape.
• Insider ownership is approximately 0.58% as of May 2025.

Annexon PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Annexon Company guides the company's strategy and oversees its operations. The board includes experienced professionals in areas such as corporate governance, research and development, and finance. Douglas Love, the President and CEO, is a board member, alongside individuals like Thomas G. Wiggans, who serves as Board Chair, and William H. Carson, MD. Other members include Jung E. Choi, Bettina M. Cockroft, M.D., William “BJ” Jones, Muneer Satter, and Will Waddill. This diverse group brings a range of expertise to the company.

Muneer Satter, a managing partner at Satter Investment Management, is a significant individual shareholder in Annexon ownership. As of December 31, 2024, he held 7,406,024 shares. This substantial ownership stake highlights the importance of individual investors in the company's structure and the influence they can exert through their holdings. The board's composition and the ownership structure are crucial factors for understanding the company's direction and governance.

Annexon's authorized capital stock consists of 300,000,000 shares of common stock and 5,000,000 shares of preferred stock. Each common stock share entitles the holder to one vote on all matters, including director elections. Director elections are determined by a plurality of votes. General matters are decided by a majority vote, but certain actions, such as amending the certificate of incorporation, require a 66 2/3% vote. The board can also issue preferred stock with varied rights, potentially affecting the voting power of common stockholders. Understanding the voting structure is key for anyone researching the Competitors Landscape of Annexon.

Voting Power and Shareholder Influence

Shareholders of Annexon Company have specific voting rights that influence company decisions. The board's composition and the voting structure are critical for understanding how the company is governed and how decisions are made. The presence of significant shareholders, like Muneer Satter, can have a notable impact on the company's direction.

• Each common stock share has one vote.
• Director elections are decided by a plurality of votes.
• Certain actions require a supermajority vote.
• Preferred stock can affect common stockholder voting power.

Annexon Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the past few years, the ownership landscape of the Annexon Company has seen significant developments, primarily marked by sustained institutional interest and strategic financial maneuvers. As of May 2025, the ownership structure is heavily influenced by institutional investors, with 337 institutional owners holding a substantial total of 123,243,946 shares. This indicates a strong vote of confidence from the financial community. Mutual funds have also increased their stake, growing from 51.65% in April 2025 to 52.88% in May 2025, reflecting growing confidence in the company's trajectory. Conversely, insider ownership remains relatively modest, accounting for approximately 0.58% as of May 2025.

The company's approach to talent acquisition and retention is also evident in its stock option grants. In May 2025, Annexon Biosciences granted stock options to new non-executive employees, allowing them to purchase 214,000 shares. This follows a similar move in April 2025, where options for 105,000 shares were granted, all under the 2022 Employment Inducement Award Plan. These options typically vest over several years, which aligns employee interests with the long-term success of the company. These actions are a part of a broader trend in the biotech industry, where attracting and retaining top talent is crucial for driving innovation and achieving clinical milestones.

The financial health of Annexon Company, particularly its cash position, plays a crucial role in shaping future ownership trends. As of March 31, 2025, the company reported $263.7 million in cash and investments. This robust financial standing provides a solid runway, extending into the second half of 2026, to support its late-stage programs. Such financial strength can influence investor sentiment and potentially facilitate strategic partnerships, further research and development initiatives, or even acquisitions. The ongoing progress of the company's clinical pipeline, with key milestones expected in 2025 and 2026, will be critical in determining the future ownership dynamics. For more insights into the company's strategic direction, consider reading about the Growth Strategy of Annexon.

Institutional Ownership

Institutional ownership is a key factor in Annexon ownership, with a significant number of shares held by institutional investors. The trend shows sustained interest from institutional investors, who often make long-term investment decisions.

Insider Ownership

Insider ownership, while present, represents a smaller percentage of the total shares. This indicates the level of alignment between company insiders and the broader investor base. It's a common aspect of biotech company ownership.

Cash Position and Financial Runway

The company's strong cash position, as of March 31, 2025, provides a financial runway that supports its late-stage programs into the second half of 2026. This financial stability is crucial for maintaining operational momentum and achieving key milestones.

Stock Options and Employee Incentives

The granting of stock options to new employees reflects the company's commitment to attracting and retaining talent. These options are designed to align employee interests with the company's long-term success and are a common practice in the pharmaceutical company sector.

Annexon Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs